Biotech

Biotech Andrew Joseph

STAT Plus: Detailed data on Alnylam’s heart drug show substantial benefit, while competition likely awaits

Biotech Andrew Joseph

STAT Plus: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows

Biotech Elaine Chen

STAT Plus: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Thoughts, takes, and burning biotech questions as the beginning of the end of the year approaches

The Readout Meghana Keshavan

STAT Plus: Genentech is shedding even more employees

Biotech Elaine Chen

STAT Plus: Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats

The Readout Elaine Chen

STAT Plus: Hims takes a blow from Lilly’s vial news

Biotech Adam Feuerstein

STAT Plus: Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial

The Readout Elaine Chen

STAT Plus: Pfizer and Lilly want to sell you drugs directly

Health tech Katie Palmer

STAT Plus: To help migraine patients — and sell more medicines — major drugmakers turn to telehealth

Biotech Elaine Chen

STAT Plus: Lilly launches Zepbound vials in move that could ease supply constraints

The Readout Meghana Keshavan

STAT Plus: A Galapagos investor signals impatience with its turnaround efforts

Exclusive Jason Mast

STAT Plus: Biden administration’s $3.2 billion antiviral pandemic plan is fizzling out

Biotech Jason Mast

STAT Plus: Tome Biosciences files notice to lay off virtually entire staff

Exclusive Jason Mast and Allison DeAngelis

STAT Plus: Tome Biosciences, once a high-flying gene-editing startup, is floundering

Biotech Andrew Joseph

STAT Plus: U.K.’s cost-effectiveness agency gives negative review of Alzheimer’s drug Leqembi

Biotech Jonathan Wosen

STAT Plus: Gene therapy pioneer Jim Wilson believes he can commercialize rare-disease drugs in a tough climate

Politics John Wilkerson

STAT Plus: Congressional probe questions clinical trials run in China, citing army involvement

Health Elaine Chen

STAT Plus: Does Ozempic increase the risk of suicidal thoughts?

Health tech Mohana Ravindranath

STAT Plus: Carbon Health founder steps back from top role, Kaiser hospitals roll out AI scribe

Biotech Elaine Chen

STAT Plus: Lilly’s Zepbound slashed risk of developing diabetes

Biotech Elaine Chen, Andrew Joseph, and Adam Feuerstein

STAT Plus: What to know about Alnylam’s upcoming readout on its heart drug 

Biotech Allison DeAngelis

STAT Plus: AI drug firm Recursion seeks to move from survival to industry domination

Exclusive Meghana Keshavan

STAT Plus: Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy

The Readout Meghana Keshavan

STAT Plus: Is pharma still fearful of the Inflation Reduction Act?

Biotech Matthew Herper

STAT Plus: Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback

Biotech Meghana Keshavan

STAT Plus: Lykos Therapeutics cuts 75% of staff after FDA rejects MDMA-assisted therapy

Biotech Jon Chesto — Boston Globe

STAT Plus: Boston’s lab market is in rough shape

Biotech Adam Feuerstein

STAT Plus: The business of CRISPR’d medicine: Not great